Clinical Updatesacute myeloid leukemiaCD7 CAR-T
CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives
By MedXY|Jul 13, 2026
This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.